Resolute Science develops first-in-class synthetic drug conjugates, known as Macrophage-Targeted Conjugates (MAC-TACs), for treating solid tumors. This platform leverages tumor-associated macrophages (TAMs) to deliver cytotoxic or radiotherapeutic payloads, bypassing common cancer resistance mechanisms. The company aims to provide effective, well-tolerated targeted therapeutics for late-stage cancers where conventional options are exhausted.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors are aggressive, difficult to treat, and prone to developing drug resistance, leading to recurrence and poor patient outcomes. Current cancer therapies often fail due to tumor heterogeneity and the inability to effectively deliver cytotoxic payloads deep within the tumor microenvironment.
Solution
Resolute Science is developing a novel class of pan-cancer therapeutics based on its MAC-TACs (Macrophage Targeted Conjugates) technology platform. This platform harnesses the power of tumor-associated macrophages (TAMs) to selectively deliver cytotoxic payloads directly to solid tumors. By leveraging TAMs, MAC-TACs can overcome common resistance mechanisms associated with direct targeting of cancer cells, offering a potential solution to tumor heterogeneity and recurrence. The MAC-TACs platform is designed to be biomarker-driven and tumor-agnostic, with the potential for broad applicability across multiple solid tumor types. This approach aims to improve both the safety and efficacy of cancer treatment compared to existing standards of care.
Target Audience
The primary target audience includes patients with aggressive, difficult-to-treat, and rare solid tumors, as well as oncologists and researchers seeking novel therapeutic approaches.
Features
- MAC-TACs (Macrophage Targeted Conjugates) technology platform for targeted drug delivery
- Utilizes tumor-associated macrophages (TAMs) to deliver cytotoxic payloads
- Designed to overcome cancer recurrence and evolved resistance
- Biomarker-driven approach for personalized therapy
- Tumor-agnostic platform applicable to a wide range of solid tumors